MA27701A1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
MA27701A1
MA27701A1 MA28303A MA28303A MA27701A1 MA 27701 A1 MA27701 A1 MA 27701A1 MA 28303 A MA28303 A MA 28303A MA 28303 A MA28303 A MA 28303A MA 27701 A1 MA27701 A1 MA 27701A1
Authority
MA
Morocco
Prior art keywords
chemical compounds
new chemical
hyak3 proteins
imbalance
proteins
Prior art date
Application number
MA28303A
Other languages
English (en)
Inventor
Hasegawa Masaichi
Tang Jun
Sato Hideyuki
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA27701A1 publication Critical patent/MA27701A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention se rapporte à des composés nouvellement identifiés comme inhibant les protéines hYAK3 et à des méthodes pour traiter les maladies associées au déséquilibre ou à l'activité inappropriée des protéines hYAK3.
MA28303A 2002-11-22 2005-05-27 Nouveaux composes chimiques MA27701A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42838402P 2002-11-22 2002-11-22

Publications (1)

Publication Number Publication Date
MA27701A1 true MA27701A1 (fr) 2006-01-02

Family

ID=32393394

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28303A MA27701A1 (fr) 2002-11-22 2005-05-27 Nouveaux composes chimiques

Country Status (31)

Country Link
US (1) US7767701B2 (fr)
EP (1) EP1567112B1 (fr)
JP (1) JP2006509765A (fr)
KR (1) KR20050085115A (fr)
CN (1) CN100579978C (fr)
AP (1) AP1967A (fr)
AR (1) AR045407A1 (fr)
AT (1) ATE411302T1 (fr)
AU (1) AU2003298693B2 (fr)
BR (1) BR0316502A (fr)
CA (1) CA2507256A1 (fr)
CY (1) CY1108655T1 (fr)
DE (1) DE60324178D1 (fr)
DK (1) DK1567112T3 (fr)
EA (1) EA008865B1 (fr)
EC (1) ECSP055808A (fr)
ES (1) ES2315566T3 (fr)
HK (1) HK1083443A1 (fr)
IS (1) IS2659B (fr)
MA (1) MA27701A1 (fr)
MX (1) MXPA05005406A (fr)
MY (1) MY140132A (fr)
NO (1) NO20052928L (fr)
NZ (1) NZ539873A (fr)
OA (1) OA12963A (fr)
PL (1) PL377564A1 (fr)
PT (1) PT1567112E (fr)
SI (1) SI1567112T1 (fr)
TW (1) TWI309648B (fr)
UA (1) UA80572C2 (fr)
WO (1) WO2004047760A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
EP1648889B1 (fr) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Sel d'isethionate d'un inhibiteur selectif de la cdk4
JP4908210B2 (ja) * 2003-07-28 2012-04-04 メルク セローノ ソシエテ アノニム Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
NZ547962A (en) 2003-11-21 2010-06-25 Actelion Pharmaceuticals Ltd 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatices as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
WO2005082901A1 (fr) * 2004-02-25 2005-09-09 Smithkline Beecham Corporation Nouveaux composes chimiques
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
CA2571738A1 (fr) 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Quinolines insubstituees thiazolinone
ES2317238T3 (es) * 2004-07-01 2009-04-16 F. Hoffmann-La Roche Ag Quinolina-tiazolinonas con actividad antiproliferante cdk-1.
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
AU2005293556A1 (en) * 2004-10-12 2006-04-20 Merck Serono Sa PI3 Kinase gamma inhibitors for the treatment of anaemia
KR100890533B1 (ko) * 2004-10-14 2009-03-27 에프. 호프만-라 로슈 아게 Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논
ATE388149T1 (de) * 2004-10-14 2008-03-15 Hoffmann La Roche Neue azaindol-thiazolinone als krebsmittel
US7268231B2 (en) 2004-10-14 2007-09-11 Hoffmann-La Roche Inc. 1,5-Naphthyridine azolinone
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
AR053602A1 (es) * 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
JP2008545690A (ja) * 2005-05-23 2008-12-18 スミスクライン・ビーチャム・コーポレイション 新規化合物
JP2008543769A (ja) * 2005-06-08 2008-12-04 スミスクライン・ビーチャム・コーポレイション （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン
TW200716580A (en) * 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
WO2007056683A2 (fr) * 2005-11-08 2007-05-18 Smithkline Beecham Corporation Nouveaux composés chimiques
JP2009528383A (ja) * 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
WO2007103758A2 (fr) * 2006-03-02 2007-09-13 Smithkline Beecham Corporation Thiazolones utilisés en tant qu'inhibiteurs de p13-kinases
KR100752757B1 (ko) * 2006-04-05 2007-08-29 한국과학기술연구원 2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
KR20090007609A (ko) * 2006-04-25 2009-01-19 더 클리브랜드 클리닉 파운데이션 ＲＮａｓｅ Ｌ을 활성화시키는 항-바이러스 제제
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
DK2094676T3 (da) * 2006-11-23 2013-06-10 Actelion Pharmaceuticals Ltd Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
JPWO2010122979A1 (ja) 2009-04-20 2012-10-25 Ｓｂｉバイオテック株式会社 チアゾリジノン誘導体
CA2880487C (fr) * 2012-07-30 2018-07-24 Kyoto University Utilisation d'un compose et d'une composition pharmaceutique pour un trouble neuropsychologique ou une tumeur maligne
CA2895172C (fr) 2012-08-17 2020-08-18 Actelion Pharmaceuticals Ltd Procede de preparation de (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-|(o-tolyl)thiazolidin-4-one et intermediaire utilise dans ledit procede
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
MX2016015627A (es) * 2014-05-28 2017-05-04 Universität Bern Compuesto de tiazolidinona y su uso en el tratamiento de trastornos psiquiátricos o neurológicos y de la inflamación, en particular de la neuroinflamación.
CN104370852B (zh) * 2014-11-26 2016-04-20 山东大学 一种噻唑烷酮类化合物及其在制备治疗铁紊乱相关疾病药物中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1548312A (fr) * 1967-06-06 1968-12-06
JPS5545648A (en) 1978-09-29 1980-03-31 Teikoku Hormone Mfg Co Ltd 2-formyldibenzazepin derivative and its preparation
HU188852B (en) * 1983-03-16 1986-05-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer
SU1611216A3 (ru) * 1986-12-29 1990-11-30 Пфайзер Инк (Фирма) Способ получени производных тиазолидиндиона или их фармацевтически приемлемых солей с щелочными металлами
EP0304493B1 (fr) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Derives d'hydroxystyrene
JPH0197926A (ja) 1987-10-09 1989-04-17 Idemitsu Kosan Co Ltd 有機非線型光学材料
DD270072A1 (de) 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5145753A (en) * 1989-09-12 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Solid electrolyte fuel cell
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
JP3393645B2 (ja) * 1991-02-08 2003-04-07 ウェルスタット セラピューティクス コーポレイション 造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体
JP3155050B2 (ja) 1991-02-28 2001-04-09 富士通株式会社 荷電粒子ビームを用いた露光方法
EP0554834B1 (fr) 1992-02-03 1998-06-03 Fuji Photo Film Co., Ltd. Procédé de dispersion d'un colorant et matériau photographique à l'halogénure d'argent contenant un colorant
JP2835246B2 (ja) 1992-06-02 1998-12-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
EP0587377A3 (en) 1992-09-10 1994-09-21 Lilly Co Eli Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease
EP0587229B1 (fr) 1992-09-11 2002-05-08 Agfa-Gevaert Element photographique contenant un colorant-filtre pour applications avec traitement rapide
EP0587230B1 (fr) 1992-09-11 2003-11-26 Agfa-Gevaert Element photographique contenant un colorant-filtre pour applications avec traitement rapide
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
JP3871354B2 (ja) 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JPH08109176A (ja) 1994-10-07 1996-04-30 Torii Yakuhin Kk イソローダニンｎ酢酸誘導体
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5618835A (en) * 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JPH09255669A (ja) 1996-03-22 1997-09-30 Hisamitsu Pharmaceut Co Inc 新規なベンジリデン誘導体
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
UY24886A1 (es) 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
US6211209B1 (en) * 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
WO1999059586A1 (fr) 1998-05-19 1999-11-25 Regents Of The University Of California Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6689491B1 (en) * 1999-02-08 2004-02-10 Fuji Photo Film Co., Ltd. Luminescent device material, luminescent device using the same, and amine compound
US6372742B1 (en) 1999-07-01 2002-04-16 Geron Corporation Substituted indole compounds and methods of their use
JP2001348520A (ja) * 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
CA2384041A1 (fr) 2000-07-05 2002-01-24 Synaptic Pharmaceuticals Corporation Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
DE10115227A1 (de) * 2001-03-28 2002-12-19 Bayer Ag Optischer Datenträger enthaltend in der Informationsschicht eine lichtabsorbierende Verbindung mit mehreren chromophoren Zentren
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer

Also Published As

Publication number Publication date
PL377564A1 (pl) 2006-02-06
EA008865B1 (ru) 2007-08-31
CY1108655T1 (el) 2014-04-09
AU2003298693B2 (en) 2010-09-30
SI1567112T1 (sl) 2009-02-28
UA80572C2 (en) 2007-10-10
AP1967A (en) 2009-03-10
ATE411302T1 (de) 2008-10-15
AU2003298693A1 (en) 2004-06-18
NO20052928D0 (no) 2005-06-15
WO2004047760A2 (fr) 2004-06-10
TWI309648B (en) 2009-05-11
MXPA05005406A (es) 2005-08-03
EP1567112B1 (fr) 2008-10-15
OA12963A (en) 2006-10-13
US7767701B2 (en) 2010-08-03
AP2005003304A0 (en) 2005-06-30
CN1742010A (zh) 2006-03-01
KR20050085115A (ko) 2005-08-29
EP1567112A4 (fr) 2006-11-15
CA2507256A1 (fr) 2004-06-10
PT1567112E (pt) 2009-01-08
IS2659B (is) 2010-08-15
EA200500856A1 (ru) 2005-10-27
EP1567112A2 (fr) 2005-08-31
AR045407A1 (es) 2005-10-26
WO2004047760A3 (fr) 2004-10-21
MY140132A (en) 2009-11-30
BR0316502A (pt) 2005-10-04
US20060293338A1 (en) 2006-12-28
CN100579978C (zh) 2010-01-13
TW200418819A (en) 2004-10-01
ES2315566T3 (es) 2009-04-01
NZ539873A (en) 2008-09-26
DE60324178D1 (de) 2008-11-27
ECSP055808A (es) 2005-09-20
DK1567112T3 (da) 2009-02-09
HK1083443A1 (en) 2006-07-07
IS7879A (is) 2005-06-02
NO20052928L (no) 2005-08-17
JP2006509765A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
MA27701A1 (fr) Nouveaux composes chimiques
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
ATE435232T1 (de) Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
WO2000047583A8 (fr) Pyrrolo-carbazoles et iso-indolones cycliques substitues condenses
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
TNSN02011A1 (fr) Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
MA30340B1 (fr) Nouveaux composes
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
SG149045A1 (en) Novel fused pyrrolocarbazoles
ATE340785T1 (de) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
DE60028195D1 (de) Proteine und nukleinsäuremoleküle des kopfes, des nervenkords, der tieferen darmabschnitte und des malpighi-gefässes des flohs und ihre verwendungen
CY1107362T1 (el) Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3
DE60222286D1 (de) Verfahren zur erhöhung des testosteronspiegels
Malík et al. Expression of attractin and its differential enzyme activity in glioma cells
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
PT1141305E (pt) Gene quimerico formado pelas sequencias de adn que codifica os determinantes antigenicos de quatro proteinas de l. infantum
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
WO1998024887A3 (fr) Proteines transglutaminases des nematodes parasites, molecules d'acide nucleique et leurs utilisations